Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Gene expression signature of gemcitabine resistance in human gastric cancer cell line

ABSTRACT: We examined the microarray-based expression profiles of the cells to identify genes associated with gemcitabine resistance

ORGANISM(S): Homo sapiens

PROVIDER: GSE58118 | GEO | 2015/05/01

SECONDARY ACCESSION(S): PRJNA248982

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Gene expression signature of gemcitabine resistance in human gastric cancer cell line

Project description:We examined the microarray-based expression profiles of the cells to identify genes associated with gemcitabine resistance Using a set of parental and gemcitabine resistant cell line, MKN28 and RMKN28, we studied mRNA transcription levels by microarray analysis to see if there are any of the key molecules for development of acquisition of the GEM resistance.

2015-05-01 | E-GEOD-58118 | biostudies-arrayexpress

Gene expression signature of gemcitabine resistance in human pancreatic cancer cell lines

Project description:We examined the microarray-based expression profiles of the cells to identify genes associated with gemcitabine resistance Using three set of parental and resistant cell lines, PK-9 and RPK-9, PK-1 and RPK-1, and PK-59 and RPK-59, we studied mRNA transcription levels by microarray analysis to see if there are any of the key molecules for development of acquisition of the GEM resistance.

2012-05-08 | E-GEOD-35141 | biostudies-arrayexpress

DCK is frequently inactivated in acquired gemcitabine-resistant human cancer cells.

Project description:We examined the microarray-based expression profiles of the cells to identify genes associated with gemcitabine resistance

2012-05-09 | GSE35141 | GEO

Profiling the Panc1 pancreatic cancer cell line following Gemcitabine treatment using single cell RNA sequencing

Project description:Pancreatic ductal adenocarcinoma (PDAC) often presents at late clinical stages, and most patients are managed solely through palliative chemotherapy. With no approved treatment modalities for patients who progress on broad-spectrum chemotherapy, we set to identify druggable targets to prevent or reverse resistance to the first line anti-neoplastic Gemcitabine. In our first experiment, we used the well-established Panc1 cell line as an in vitro model of PDAC. Panc1 cells were incubated with a tolerable dose of Gemcitabine in vitro, and examined alterations in gene expression via single cell RNA sequencing. In our subsequent studies, we incubated Panc1 cells with increasing doses of Gemcitabine for several passages, until viable in approximately 10x the known IC50 value. These cells were designated Panc1-GR. Based on our observations in the prior experiment, Panc1-GR cells were compared to those treated with wither the Calmodulin inhibitor W-7, Calcium chelator BAPTA-AM, or the calcium channel blocker Amlodipine. Through these efforts, we hope to better understand the mechanisms of Gemcitabine resistance in PDAC, as well as introduce new therapeutic strategies to reverse drug resistant phenotypes in the clinic.

2022-03-21 | GSE186960 | GEO

Exploring Transcriptional alterations in the Development of Gemcitabine Resistance [AsPC1R_vs_AsPC1_RNAseq]

Project description:To investigate the transcriptional alterations that occur during the development of gemcitabine resistance in pancreatic cancer cells, we established gemcitabine-resistant AsPC1 cells, referred to as AsPC1R. We then employed RNA-seq to explore the transcriptome changes between the gemcitabine-resistant cells and their parental counterparts.

2024-09-23 | GSE247163 | GEO

Exploring Transcriptional alterations in the Development of Gemcitabine Resistance [SW1990R_vs_SW1990_RNAseq]

Project description:To investigate the transcriptional alterations that occur during the development of gemcitabine resistance in pancreatic cancer cells, we established gemcitabine-resistant SW1990 cells, referred to as SW1990R. We then employed RNA-seq to explore the transcriptome changes between the gemcitabine-resistant cells and their parental counterparts.

2024-09-23 | GSE247165 | GEO

Transcriptomic data from a gallbladder cancer cell line with acquired chemoresistance to gemcitabine [TGBC1]

Project description:Gallbladder cancer (GBC) has few therapeutic options, being gemcitabine the first-line chemotherapeutic drug. However, this treatment shows poor clinical outcomes on patients. The acquired resistance phenomenon during of the treatment is one of the main factors that leads to insufficient therapeutic effects, and the molecular mechanisms used by tumor cells against gemcitabine are still poorly understood. First, we established a GBC cell line with acquired resistance to gemcitabine (TGBC1 GemR) from parental cell line (TGBC1). After, we used microarray hybridization in TGBC1 and TGBC1 GemR to characterize their transcriptional profile to identify differentially expressed genes and/or molecular pathways involved chemoresistant cell phenotype.

2022-07-21 | GSE208660 | GEO

Transcriptomic data from a gallbladder cancer cell line with acquired chemoresistance to gemcitabine [NOZ]

Project description:Gallbladder cancer (GBC) has few therapeutic options, being gemcitabine the first-line chemotherapeutic drug. However, this treatment shows poor clinical outcomes on patients. The acquired resistance phenomenon during of the treatment is one of the main factors that leads to insufficient therapeutic effects, and the molecular mechanisms carried out by tumor cells against gemcitabine are still poorly understood. First, we established a GBC cell line with acquired resistance to gemcitabine (NOZ GemR) from parental cell line (NOZ). After, we used microarray hybridization in NOZ and NOZ GemR to characterize their transcriptional profile to identify differentially expressed genes and/or molecular pathways involved chemoresistant cell phenotype.

2022-07-21 | GSE208659 | GEO

Gene expression signature of paclitaxel resistance in human esophageal squamous cell cancer cell line

Project description:We examined the microarray-based expression profiles of the cells to identify genes associated with paclitaxel resistance

2016-11-29 | GSE86099 | GEO

Gene expression associated with gemcitabine resistance and its reversal by bexarotene

Project description:Resistance of Calu3 NSCLC cells to the cytotoxic nucleoside analog gemcitabine (2',2'-difluorodeoxycytidine) can be prevented as well as reversed by the rexinoid X receptor selective agonist bexarotene. This study was designed to investigate the changes in gene expression associated with gemcitabine resistance and its reversal by bexarotene. In addition to the parental Calu3 cells and the 10 cycles of treatment of the gemcitabine resistant Calu3 cells with vehicle or bexarotene, analogous treatment paradigms with gemcitabine alone as well as the combination of both compounds have been included as controls. (However, it has to be noted that in the combination treatment, cells that were re-sensitized by bexarotene have largely been removed from the culture before harvest due to the cytotoxic activity of gemcitabine.) Keywords: cell type comparison, compound effects

2007-01-31 | GSE6914 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data